Long-Acting HIV Treatment Is Coming. Our Health Care System Needs to Prepare

Kenyon Farrow

New conversations are starting in HIV care as phase III trials have shown that monthly injections of cabotegravir and rilpivirine (Edurant) are non-inferior to a three-drug pill regimen. In 2018, TheBody asked a range of people living with HIV about their willingness to switch to an injectible, and most had mixed feelings. But even if there’s widespread interest in this new way of taking antiretroviral therapy (and most likely also prevention, not too far away), it’s important to consider not just the willingness of people to move to this new form of treatment, but whether health care systems and providers in the U.S. are ready to support this innovation.

 

 Read more here